Aggressive Lymphomas
From the Journals
VcR-CVAD yields high responses, ‘excellent’ survival in MCL
The moderate-intensity induction and maintenance regimen induced good responses in both younger and older patients.
News
Survival differences among AYAs with blood cancers
A new report has revealed differences in survival among adolescents and young adults (AYAs) with hematologic malignancies. The report includes...
News
Marine animals aid development of cytotoxicity assay
Researchers have looked to deep-sea creatures with the goal of creating a better cytotoxicity assay. The team harnessed the power of enzymes...
News
Overcoming resistance to ibrutinib in CLL
New research appears to explain why ibrutinib may be less effective in certain patients with chronic lymphocytic leukemia (CLL). It seems the...
Conference Coverage
DLBCL survivors at greater risk of autoimmune, infectious diseases
ATLANTA—A population-based study indicates that, compared to other cancer survivors, patients who survive diffuse large B-cell lymphoma (DLBCL)...
News
Brentuximab vedotin sBLA receives priority review
The US Food and Drug Administration (FDA) has accepted for priority review a supplemental biologics license application (sBLA) for brentuximab...
Conference Coverage
BTK inhibitor zanubrutinib active in non-Hodgkin lymphomas
ATLANTA – Response rates ranged from 31% to 88% depending on the lymphoma subtype.
News
Update reveals ongoing responses in ZUMA-1
ATLANTA—The chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel; KTE-C19) is showing consistent, ongoing responses...
News
Research explains why cisplatin causes hearing loss
Researchers have gained new insight into hearing loss caused by cisplatin. By measuring and mapping cisplatin retention in mouse and human inner...
Conference Coverage
Chemo-free combo should be option for rel/ref CLL, doc says
ATLANTA—The combination of venetoclax and rituximab (VR) should be a standard treatment option for adults with relapsed/refractory chronic...
Conference Coverage
Risk stratification may be possible with JCAR017
ATLANTA—Data suggest a therapeutic window may exist for chimeric antigen receptor (CAR) T-cell expansion with JCAR017, according to a preliminary...